ImStem Biotechnology

AgeX Therapeutics Sublicenses Stem Cell Line ESI-053 to ImStem Biotechnology for Development of Cell Therapy Candidate IMS001 for COVID-19 and Acute Respiratory Distress Syndrome

Retrieved on: 
Wednesday, October 28, 2020
Biotechnology, Health, Stem cells, Pharmaceutical, Clinical trials, Branches of biology, Biology, Life sciences, Stem cells, Induced stem cells, Biotechnology, Cell biology, Cloning, Stem-cell line, Cell therapy, AgeX Therapeutics, ImStem Biotechnology, ES Cell International

This ultimately led to research and commercial sublicense agreements for the ESI-053 ESC line by ImStem to develop IMS001 as an allogeneic, off-the-shelf and industrially scalable MSC product candidate.

Key Points: 
  • This ultimately led to research and commercial sublicense agreements for the ESI-053 ESC line by ImStem to develop IMS001 as an allogeneic, off-the-shelf and industrially scalable MSC product candidate.
  • IMS001 is believed to be the first MSC product derived from an ESC line to be accepted for a human trial by the FDA.
  • We are glad to expand our relationship with ImStem, so it can now utilize AgeXs ESI-053 stem cell line to develop its cell therapy candidate IMS001 for COVID-19 as well as acute respiratory distress syndrome more broadly, said Dr. Nafees Malik, Chief Operating Officer of AgeX.
  • The ESI stem cell lines are distinguished as the first clinical-grade human pluripotent stem cell lines created under current Good Manufacturing Practice as described in Cell Stem Cell (2007;1:490-4).

AgeX Therapeutics and ImStem Biotechnology Sign Non-Binding Letter of Intent Regarding Investigational MSC Candidate IMS001 for COVID-19 and Other Causes of ARDS

Retrieved on: 
Tuesday, June 2, 2020
Health, Infectious diseases, Stem cells, Pharmaceutical, Cardiology, Biotechnology, Multiple sclerosis, AgeX Therapeutics, ImStem Biotechnology

AgeX and ImStem are co-operating to finalize financial terms and other provisions of a license agreement.

Key Points: 
  • AgeX and ImStem are co-operating to finalize financial terms and other provisions of a license agreement.
  • ImStem has previously used AgeX ESI 053 to derive the ImStem IMS001 product which is being investigated for multiple sclerosis under an IND.
  • AgeX and ImStem already have a commercial license in place, which grants ImStem rights to use AgeXs ESI 053 to derive IMS001 as a product candidate for development in autoimmune disease, including multiple sclerosis.
  • To date, in patients with pneumonia and ARDS due to COVID-19, preliminary literature suggests MSCs, such as ImStems hES-MSC candidate IMS001, may warrant further development consideration.

AgeX Therapeutics Licensee ImStem Biotechnology Announces FDA has Lifted the Hold and Cleared the Investigational New Drug Application for IMS001 for the Treatment of Multiple Sclerosis

Retrieved on: 
Friday, March 20, 2020
Research, Medical devices, FDA, Clinical trials, Stem cells, Biotechnology, Health, Pharmaceutical, Science, Immunogenicity, Immunology, AgeX Therapeutics, Health, AgeX Therapeutics, IMS001, ImStem Biotechnology

This collaboration with ImStem is consistent with our aim to make our clinical-grade pluripotent stem cell banks widely available for diverse therapeutic applications.

Key Points: 
  • This collaboration with ImStem is consistent with our aim to make our clinical-grade pluripotent stem cell banks widely available for diverse therapeutic applications.
  • ImStem plans to initiate a phase 1 clinical study in patients with relapsing-remitting, secondary, and primary progressive forms of MS in 2020 in the US.
  • AgeX Therapeutics, Inc. (NYSE American: AGE) is focused on developing and commercializing innovative therapeutics for human aging.
  • IMS001 is an investigational, allogeneic, hES-MSC that has undergone IND-enabling, preclinical biodistribution, engraftment, tumorigenicity, toxicology, immunogenicity, and pharmacology studies.